12/15/2016 - 2:43pm

Walgreens ranks the top markets and states for flu activity in the U.S. It's the third year for Walgreens' Flu Index, and this year will include Puerto Rico for the first time.

12/15/2016 - 1:06pm

The drug’s availability comes a year after the Food and Drug Administration approved it as a follow-on biologic to Lantus, another U-100 long-acting insulin. It has an amino acid sequence identical to that of Lantus. 

12/14/2016 - 4:32pm

Pfizer's Eucrisa came into its portfolio in May with the company’s acquisition of Anacor Pharmaceuticals, and Pfizer projects that it could bring in $2 billion or more in annual sales. 

12/13/2016 - 1:31pm

The drug is indicated to improve blood sugar in adults with Type 2 diabetes when both empagliflozin and metformin can be taken.

12/13/2016 - 12:46pm

Eli Lilly & Co. has outlined a new initiative, set to begin Jan. 1, 2017, that will offer access to Lilly insulin at discounted prices to patients via Blink Health’s mobile and web platforms through a partnership with Express Scripts. 

12/09/2016 - 11:55am
The focus of the initiative, which will see Lilly making an upfront payment of $30 million to AstraZeneca, is an antibody called MEDI1814, which can potentially slow the progression of the illness and is currently in Phase 1 trials. 
12/09/2016 - 9:06am

London Drugs is hoping to beat Shoppers Drug Mart to market in terms of dispensing medical marijuana, Canada's Tri-City News reported Thursday. “We’ll be as fast as the laws allow," London Drugs VP John Tse told the Candadian daily, "but it could happen overnight, we’re that ready." London Drug pharmacists are already reviewing potential drug-drug interactions. "We're interested from the perspective of how does it affect other medication the patient might be on and other health conditions they might have,” Tse said. “As a pharmacy we want it all documented properly so that we can advise patients and other health care professionals.” (Tri-City News)

12/08/2016 - 4:04pm

The company told USA Today the cuts would take effect Feb. 10, with its Fairfax, Delaware headquarters seeing about 120 of the expected cuts, with other impacted roles spanning those that are field-based in both sales and non-sales. 

12/08/2016 - 1:03pm

In addition to returning the rights to Belbuca to BioDelivery Sciences International, Endo will be eliminating its 375-member pain sales field force in an effort to refocus its U.S. branded strategy on specialty, including its Xiaflex.